How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

597 results for

Melasma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Oral tranexamic Acid for the treatment of melasma. (PubMed)

Oral tranexamic Acid for the treatment of melasma. Melasma poses a great challenge as its treatment is unsatisfactory and recurrence is high. Treatment of melasma using tranexamic acid (oral, topical or intralesional) is a novel concept.To compare the efficacy of oral tranexamic acid with routine topical therapies for the treatment of melasma.It is a prospective, interventional, randomized controlled trial conducted among 260 melasma patients. Patients were divided into two groups consisting (...) of 130 patients each. First group (Group A) was given routine treatment measures and oral Tranexamic Acid while second group (Group B) was treated only with routine topical measures. Capsule Tranexamic Acid was prescribed at a dose of 250 mg twice a day for three months and cases were followed for three months. Response was evaluated on the basis of Melasma Assessment Severity Index (MASI). Mean scores between the two groups were then compared.Statistically significant decrease in the mean Melasma

2013 Kathmandu University medical journal (KUMJ)

182. Histopathological study of the treatment of melasma lesions using a low-fluence Q-switched 1064-nm neodymium:yttrium-aluminium-garnet laser. (PubMed)

Histopathological study of the treatment of melasma lesions using a low-fluence Q-switched 1064-nm neodymium:yttrium-aluminium-garnet laser. The low-fluence 1064-nm Q-switched neodymium:yttrium-aluminium-garnet (QSNY) laser is a widely used treatment for melasma in East Asia, although its mechanism of action is unclear. The aim of this study was to elucidate the mechanism of action of the QSNY laser. We performed a histopathological study on eight Korean women who had considerable improvement (...) in their melasma lesions after a series of low-fluence QSNY laser treatments. Compared with nonlesional skin, samples from melasma lesions showed increased reactivity in melanin (Fontana-Masson staining) and in melanogenesis-associated proteins, including α-melanocyte-stimulating hormone, tyrosinase, tyrosinase-related protein (TRP)-1, TRP-2, nerve growth factor and stem cell factor. After laser treatment, the melasma skin showed a decrease in the number of melanosomes and reduced expression of melanogenesis

2013 Clinical & Experimental Dermatology

183. Split-Face Study Using a 1,927-nm Thulium Fiber Fractional Laser to Treat Photoaging and Melasma in Asian Skin. (PubMed)

Split-Face Study Using a 1,927-nm Thulium Fiber Fractional Laser to Treat Photoaging and Melasma in Asian Skin. Although the 1,927-nm thulium fiber fractional laser is effective and safe for treating photoaging, clinical data regarding this modality remain limited.To investigate the efficacy and safety of the 1,927-nm thulium fiber fractional laser for treating photoaging and melasma in Asians.Twenty-five participants received three laser treatments (at 3-week intervals) on the half of the face (...) with more-severe photoaging and melasma. Independent investigators evaluated clinical improvement 2 and 6 months after the final treatment. Improvement in melasma was evaluated using the Melasma Area and Severity Index. Subjective satisfaction rates were also evaluated. Adverse events were assessed, and pain was scored using a visual analog scale (VAS). Histologic changes were observed using immunohistochemical staining.Clinical improvement of photodamaged facial skin was remarkable on the treatment

2013 Dermatologic Surgery

184. Oral Tranexamic Acid Enhances the Efficacy of Low-Fluence 1064-Nm Quality-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial. (PubMed)

Oral Tranexamic Acid Enhances the Efficacy of Low-Fluence 1064-Nm Quality-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial. Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders.To evaluate the clinical efficacy and safety of oral TA combined with low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma.Forty-eight (...) patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low-fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale.Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from

2013 Dermatologic Surgery

185. A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma

A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01976286 Recruitment Status : Active, not recruiting First Posted : November 5, 2013 Last Update Posted : April

2013 Clinical Trials

186. A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma

A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01976273 Recruitment Status : Completed First Posted : November 5, 2013 Results First Posted : June 14

2013 Clinical Trials

187. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. (PubMed)

Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. BACKGROUND; Melasma is a common acquired chronic hypermelanosis of sun-exposed areas which significantly impacts quality of life. There are few epidemiological studies in medical literature concerning these patients.Characterize clinical and epidemiological data on Brazilian female patients with melasma.A semi-structured questionnaire was administered to melasma patients treated at a dermatology clinic (...) between 2005 and 2010. Association between variables was performed by multivariate regression models.We assessed 302 patients; intermediate skin phototypes III (34.4%) and IV (38.4%) were prevalent. Mean disease onset age was 27.5 ± 7.8 years and familiar occurrence of melasma was identified in 56.3%. The most commonly reported trigger factors were pregnancy (36.4%), contraceptive pills (16.2%) and intense sun exposure (27.2%). Preferred facial topographies were zygomatic (83.8%), labial superior

2013 Journal of the European Academy of Dermatology and Venereology

188. Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study. (PubMed)

Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study. Extra-facial melasma is a prevalent dermatosis in some populations with special characteristics in relation to its clinical aspects and probable etiopathogenic factors. Few studies have attempted to address this alteration of pigmentation, which has become a challenge in clinical Dermatology.To assess the clinical histopathological and immunohistochemical characteristics of extra-facial melasma (...) , comparing affected, and unaffected sites.Case-control study with 45 patients in each group (melasma and disease-free volunteers), assessing their clinical characteristics. In 36 patients, biopsies were performed on the lesion and the normal perilesional skin. Specimens were stained with HE and Fontana-Masson, and melanocytes analysed by immunohistochemistry. Objective measurements were accomplished by a specifically designed image analysis software.The melasma group had a mean age ± SD of 56.67 ± 8

2013 Journal of the European Academy of Dermatology and Venereology

189. Melasma pathogenesis and influencing factors - an overview of the latest research. (PubMed)

Melasma pathogenesis and influencing factors - an overview of the latest research. Melasma is an acquired, symmetrical hypermelanosis of the face. The pathogenesis of melasma is complex and the treatment is often challenging with frequent relapses. Genetic background, exposure to ultraviolet radiation, and female sex hormones are classical influencing factors. To the light of the recent literature, other factors could promote melasma lesions. Moreover, there are increasing evidences showing (...) that melanocytes are not the only cells involved, and that other players probably have a key role in the development and the relapses of melasma. Identifying those associated factors should provide new targets for a more efficient treatment of melasma and a better prevention of the relapses.© 2012 The Author. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.

Full Text available with Trip Pro

2013 Journal of the European Academy of Dermatology and Venereology

190. Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma

Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01850186 Recruitment Status : Completed First Posted : May 9, 2013 Last Update Posted

2013 Clinical Trials

191. Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators

Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01952379 Recruitment Status : Completed First Posted : September 27, 2013 Last Update Posted : November 25, 2014

2013 Clinical Trials

192. Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser (PubMed)

Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser Melasma is a common hypermelanosis of the face. The use of a classical Q-switched ruby laser (QSRL) to treat melasma is discussed controversially and is associated with frequent adverse effects, such as hyper- or hypopigmentation. Recently a fractional-mode (FRx) QSRL was developed to minimize the adverse effects of classical QSRL. The objective of this research was to evaluate the efficacy (...) and safety of a novel FRx-QSRL in the treatment of melasma in Caucasian patients.We performed a retrospective study of 25 Caucasian melasma patients (Fitzpatrick skin types I to III). Patients received one to three FRx-QSRL treatments (Tattoostar FRx, Asclepion Laser Technologies, Jena, Germany) at pulse energies of 4 to 8 J/cm2. Three blinded investigators independently evaluated the melasma area and severity index (MASI) score before treatment and at the four- to six-week follow-ups. At additional

Full Text available with Trip Pro

2013 European Journal Of Medical Research

193. Mometasone Menace in Melasma (PubMed)

Mometasone Menace in Melasma 22837578 2012 08 14 2018 11 13 1998-3611 57 4 2012 Jul Indian journal of dermatology Indian J Dermatol Mometasone menace in melasma. 324-6 10.4103/0019-5154.97686 Godse Kiran V KV Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai, India. drgodse@yahoo.co.in. Zawar Vijay V eng Journal Article India Indian J Dermatol 0370750 0019-5154 2012 7 28 6 0 2012 7 28 6 0 2012 7 28 6 1 ppublish 22837578 10.4103/0019-5154.97686 IJD-57-324 PMC3401859 Br J Dermatol

Full Text available with Trip Pro

2012 Indian journal of dermatology

194. The treatment of melasma by silymarin cream. (PubMed)

The treatment of melasma by silymarin cream. Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of this study were the assessment of safety and efficacy of topical Silymain (SM) cream in a double-blind placebo controlled study for treatment of melasma (...) patients.Experimentally on 24 Albino rabbits were randomly divided into 4 equal groups. [A] No treatment, [B] received placebo, [C] treated with SM cream (0.1), & [D] treated by SM (0.2), were applied topically before UV sun light exposure for 30 days, assessed clinically & tissue pathology. Clinically on 96 adults diagnosed with melasma randomized to three equal groups to receive one of the tested drugs applied twice daily for 4 weeks, evaluated by the response; lesion size, melasma area and severity index score

Full Text available with Trip Pro

2012 BMC dermatology

195. Is non-ablative 1550-nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single-blinded trial in 51 patients. (PubMed)

Is non-ablative 1550-nm fractional photothermolysis an effective modality to treat melasma? Results from a prospective controlled single-blinded trial in 51 patients. Melasma is a common benign pigmentary disease and can pose a substantial therapeutic challenge. Although the use of non-ablative fractional photothermolysis (NFP) has gained much popularity, there are still very few evidence-based data supporting NFP in the treatment of melasma.To assess the efficacy and safety of NFP (...) for the treatment of melasma in a controlled observer-blinded parallel-group study.Fifty-one patients [90.2% women, 9.8% men; mean age 40.3±6.1 (control group) and 41.7±11.4 (treatment group)] received a broad-spectrum sunscreen either alone (n=25; 49.0%) or in combination with a 1550-nm NFP treatment (n=26; 51.0%) [energy: 15 mJ/microthermal zone (MTZ); total density: 1048 MTZs/cm(2); density per pass: 131 MTZs/cm(2); number of passes: 8; total coverage: 20%]. Four sessions of NFP treatment were performed at 3

2012 Journal of the European Academy of Dermatology and Venereology : JEADV

196. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. (PubMed)

Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. The relapsing nature of melasma emphasizes the need to maintain efficacy achieved after acute treatment.To compare clinical efficacy and safety of two 6-month Triple Combination (TC; containing fluocinolone acetonide, hydroquinone and tretinoin) maintenance regimens in subjects with moderate to severe melasma, after daily treatment up to 8 (...) weeks.This randomized, investigator-blinded, controlled study had a maintenance phase of 6 months. Sixteen centres in Brazil and Mexico enrolled 242 subjects 18 years or older attaining no or mild melasma after 8 weeks of daily TC applications. Subjects were randomized to receive TC in a twice weekly or tapering regimen [3/week (1st month), 2/week (2nd month), 1/week (4th month)]. Efficacy and safety measurements included median time to relapse and relapse-free rate, Global Severity Score, Melasma Area

2012 Journal of the European Academy of Dermatology and Venereology : JEADV

197. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. (PubMed)

Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. The effectiveness of intense pulsed light (IPL) has been reported in adults with melasma, but there is little information about IPL with triple combination topical therapy (TC) and refractory melasma. Sixty-two patients with totally or partially refractory melasma were enrolled in this randomized open-label study. Thirty-one patients were treated (...) with IPL in a single session, bleaching agents and broad-spectrum sunscreens. Thirty-one patients were in the control group, receiving only bleaching agents and broad-spectrum sunscreens. The Melasma Area and Severity Index (MASI) and the investigator's global assessment using a seven-point scale were used to determine the impact and effectiveness of the treatment. The IPL group results based on MASI showed a 49.4% reduction (from 17.6 to 8.9; p < 0.001) after six months and a 44.9% reduction after 12

2012 Dermatologic therapy

198. PDZK1 Upregulation in Estrogen-Related Hyperpigmentation in Melasma. (PubMed)

PDZK1 Upregulation in Estrogen-Related Hyperpigmentation in Melasma. The pathogenesis of melasma is unknown, although the potential role of estrogen has been considered. Microarray and real-time PCR analyses revealed that upregulation of PDZ domain protein kidney 1 (PDZK1) is clinically correlated with melasma. Although there has been no report that PDZK1 is involved in pigmentation and/or melanogenesis, PDZK1 expression can be induced by estrogen. In this study, the role of PDZK1 upregulation (...) in melasma was examined, particularly in connection with estrogen, using biopsied skin specimens from 15 patients and monocultures and cocultures of melanocytes and keratinocytes with or without overexpression or knockdown of PDZK1. Estrogen upregulated PDZK1. Overexpression of PDZK1 increased tyrosinase expression and melanosome transfer to keratinocytes, whereas PDZK1 knockdown reduced estrogen-induced tyrosinase expression, through regulation of expression of estrogen receptors (ERs) ER-α and ER-β

Full Text available with Trip Pro

2012 Journal of Investigative Dermatology

199. The evolution of melasma therapy: targeting melanosomes using low-fluence q-switched neodymium-doped yttrium aluminium garnet lasers. (PubMed)

The evolution of melasma therapy: targeting melanosomes using low-fluence q-switched neodymium-doped yttrium aluminium garnet lasers. Melasma is an acquired disorder of pigmentation that commonly affects women with phototypes III-V, and it has a negative impact on the quality of life in affected individuals. It presents clinically as symmetric tan or brown patches on the face, most often involving the forehead, cheeks, perioral region, and periorbital region. On histologic examination (...) , and fractional lasers results in an unacceptably high rate of postinflammatory hyper- and hypopigmentation and rebound melasma. Recently, promising results have been achieved with low-fluence Q-switched neodymium-doped yttrium aluminium garnet laser treatment, which can selectively target dermal melanosomes without producing inflammation or epidermal damage, in all skin phototypes. This article reviews the current treatment modalities for melasma, the rationale for using and the clinical results

2012 Seminars in Cutaneous Medicine and Surgery

200. Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm). (PubMed)

Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm). Melasma treatment remains challenging despite various laser systems available, because of potential side-effects and high recurrence rates.Non-ablative fractionated photothermolysis (FP) is a promising therapeutic method, long-time results comparing treated vs. non-treated site are lacking.A total of 14 patients were treated with FP in a split-face mode with standardized adjustments in three (...) sessions (weeks 0, 3-4, 6-8, follow-up: 26-28). At each consultation, improvement was evaluated by patients and physicians. Objective assessment was performed using digital photographs and the pigment imaging tool SIAscope(®).Melasma improvement was registered in 83% and 75% of the cases 26-28 weeks after the first treatment based on two evaluations: by patient and by physician, respectively. Digital photography and SIAscope(®) revealed improvement in 54% and 85% after the first, 61% and 85% after

2012 Journal of the European Academy of Dermatology and Venereology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>